Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Medexus Pharmaceuticals initiated with a Buy at Roth Capital » 08:17
07/19/21
07/19
08:17
07/19/21
08:17
MEDXF

Medexus Pharmaceuticals

$6.15 /

+0.11 (+1.82%)

Roth Capital analyst…

Roth Capital analyst Scott Henry initiated coverage of Medexus Pharmaceuticals with a Buy rating and $12 price target. The analyst believes the pipeline compound treosulfan will be approved in the near-term and drive significant revenues and profitability.

ShowHide Related Items >><<
MEDXF Medexus Pharmaceuticals
$6.15 /

+0.11 (+1.82%)

MEDXF Medexus Pharmaceuticals
$6.15 /

+0.11 (+1.82%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
Hot Stocks
Medexus Pharmaceuticals appoints Marcel Konrad as CFO » 07:42
07/19/21
07/19
07:42
07/19/21
07:42
MEDXF

Medexus Pharmaceuticals

$6.15 /

+0.11 (+1.82%)

, CDNA

CareDx

$78.89 /

+0.88 (+1.13%)

Medexus Pharmaceuticals…

Medexus Pharmaceuticals (MEDXF) is pleased to announce the appointment of Marcel Konrad as CFO of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in the role. Mr. Boivin has agreed to stay on in an advisory capacity in order to help ensure an orderly transition of responsibilities to Mr. Konrad over the next approximately three months. Mr. Konrad joins the Company from CareDx, Inc. (CDNA), a precision medicine solutions company, where he has served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller since 2018, including a stint as acting Chief Financial Officer in early 2021.

ShowHide Related Items >><<
MEDXF Medexus Pharmaceuticals
$6.15 /

+0.11 (+1.82%)

CDNA CareDx
$78.89 /

+0.88 (+1.13%)

MEDXF Medexus Pharmaceuticals
$6.15 /

+0.11 (+1.82%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
CDNA CareDx
$78.89 /

+0.88 (+1.13%)

07/15/21 Craig-Hallum
CMS Billing and Coding document 'good news' for CareDx, says Craig-Hallum
06/03/21
Fly Intel: Top five analyst initiations
06/03/21 Goldman Sachs
CareDx initiated with a Buy at Goldman Sachs
05/06/21 Raymond James
CareDx price target lowered to $90 from $98 at Raymond James
CDNA CareDx
$78.89 /

+0.88 (+1.13%)

  • 21
    Jan
CDNA CareDx
$78.89 /

+0.88 (+1.13%)

Hot Stocks
Medexus Pharmaceuticals, medac enter licensing agreement for treosulfan » 09:32
07/12/21
07/12
09:32
07/12/21
09:32
MEDXF

Medexus Pharmaceuticals

$6.04 /

+0.005 (+0.08%)

Medexus Pharmaceuticals…

Medexus Pharmaceuticals announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH to commercialize treosulfan, a bifunctional alkylating agent, in Canada. Treosulfan will be marketed in Canada under the brand name Trecondyv and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation. Medexus will be responsible for selling and marketing the product, while medac will be responsible for the manufacturing and supply of the product. Medexus has been distributing treosulfan in Canada under the Special Access Program and recently received Health Canada approval to commercialize Trecondyv for the treatment of adult patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes who are at increased risk for standard conditioning therapies, as well as for pediatric patients older than one year with AML or MDS.

ShowHide Related Items >><<
MEDXF Medexus Pharmaceuticals
$6.04 /

+0.005 (+0.08%)

MEDXF Medexus Pharmaceuticals
$6.04 /

+0.005 (+0.08%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
Over a month ago
Conference/Events
Raymond James to hold a virtual conference » 04:55
06/23/21
06/23
04:55
06/23/21
04:55
TFX

Teleflex

$404.93 /

+5.265 (+1.32%)

, CBAY

CymaBay

$4.48 /

-0.26 (-5.49%)

, PYPD

PolyPid

$8.91 /

-0.11 (-1.22%)

, AYLA

Ayala Pharmaceuticals

$11.00 /

+0.3 (+2.80%)

, BWAY

Brainsway

$10.30 /

-0.1 (-0.96%)

, ENTA

Enanta

$46.35 /

+0.18 (+0.39%)

, KDMN

Kadmon

$3.83 /

-0.16 (-4.01%)

, ONCS

OncoSec

$3.40 /

+ (+0.00%)

, ATHA

Athira Pharma

$10.33 /

-0.42 (-3.91%)

, QDEL

Quidel

$111.29 /

-0.5 (-0.45%)

, CYTK

Cytokinetics

$22.15 /

+0.38 (+1.75%)

, NGM

NGM Biopharmaceuticals

$20.37 /

+0.28 (+1.39%)

, MEDXF

Medexus Pharmaceuticals

$5.69 /

-0.06 (-1.04%)

, FLXN

Flexion

$8.86 /

-0.28 (-3.06%)

, HRMY

Harmony Biosciences

$31.17 /

-0.83 (-2.59%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 21-23.

ShowHide Related Items >><<
TFX Teleflex
$404.93 /

+5.265 (+1.32%)

QDEL Quidel
$111.29 /

-0.5 (-0.45%)

PYPD PolyPid
$8.91 /

-0.11 (-1.22%)

ONCS OncoSec
$3.40 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

MEDXF Medexus Pharmaceuticals
$5.69 /

-0.06 (-1.04%)

KDMN Kadmon
$3.83 /

-0.16 (-4.01%)

HRMY Harmony Biosciences
$31.17 /

-0.83 (-2.59%)

FLXN Flexion
$8.86 /

-0.28 (-3.06%)

ENTA Enanta
$46.35 /

+0.18 (+0.39%)

CYTK Cytokinetics
$22.15 /

+0.38 (+1.75%)

CBAY CymaBay
$4.48 /

-0.26 (-5.49%)

BWAY Brainsway
$10.30 /

-0.1 (-0.96%)

AYLA Ayala Pharmaceuticals
$11.00 /

+0.3 (+2.80%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

TFX Teleflex
$404.93 /

+5.265 (+1.32%)

05/18/21 Piper Sandler
Teleflex divestiture should accelerate sales growth, says Piper Sandler
05/10/21 Piper Sandler
Teleflex management surprised by post-earnings selloff, says Piper Sandler
04/30/21 SVB Leerink
Teleflex price target raised to $485 from $475 at SVB Leerink
02/25/21 Piper Sandler
Teleflex price target raised to $465 from $405 at Piper Sandler
CBAY CymaBay
$4.48 /

-0.26 (-5.49%)

06/21/21 Piper Sandler
Piper radar 'locked' on CymaBay EASL poster presentations on June 23
06/14/21 JonesTrading
JonesTrading starts CymaBay with Buy, $8 target on seladelpar potential
06/14/21 JonesTrading
CymaBay initiated with a Buy at JonesTrading
06/09/21 Piper Sandler
CymaBay to have 'impressive' lineup at EASL meeting, says Piper Sandler
PYPD PolyPid
$8.91 /

-0.11 (-1.22%)

11/24/20 Raymond James
Raymond James upgrades PolyPid to Strong Buy after BTD for D-PLEX
11/24/20 Raymond James
PolyPid upgraded to Strong Buy from Outperform at Raymond James
08/10/20 Alliance Global Partners
PolyPid initiated with a Buy at Alliance Global Partners
07/21/20 Raymond James
PolyPid initiated with an Outperform at Raymond James
AYLA Ayala Pharmaceuticals
$11.00 /

+0.3 (+2.80%)

12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
12/02/20
Fly Intel: Top five analyst initiations
12/02/20 Noble Capital
Ayala Pharmaceuticals initiated with an Outperform at Noble Capital
BWAY Brainsway
$10.30 /

-0.1 (-0.96%)

04/20/21 Northland
Brainsway initiated with an Outperform at Northland
02/17/21 Raymond James
Brainsway price target raised to $12 from $9 at Raymond James
ENTA Enanta
$46.35 /

+0.18 (+0.39%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
KDMN Kadmon
$3.83 /

-0.16 (-4.01%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
ONCS OncoSec
$3.40 /

+ (+0.00%)

04/15/21 Alliance Global Partners
OncoSec price target raised to $11 from $6.50 at Alliance Global Partners
03/25/21 Maxim
OncoSec price target raised to $12 from $8 at Maxim
03/08/21
Fly Intel: Top five analyst initiations
03/08/21 BTIG
OncoSec initiated with a Buy at BTIG
ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

06/18/21 Jefferies
Athira Pharma's 'unusual situation' to cause some volatility, says Jefferies
06/18/21 Stifel
Athira Pharma CEO leave situation 'impossible to really vet,' says Stifel
06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
QDEL Quidel
$111.29 /

-0.5 (-0.45%)

06/17/21 Craig-Hallum
Quidel price target lowered to $219 from $296 at Craig-Hallum
06/04/21 JPMorgan
Quidel price target lowered to $80 from $90 at JPMorgan
05/07/21 JPMorgan
Quidel price target lowered to $90 from $95 at JPMorgan
04/23/21 JPMorgan
Quidel price target lowered to $95 from $120 at JPMorgan
CYTK Cytokinetics
$22.15 /

+0.38 (+1.75%)

05/11/21 Mizuho
Cytokinetics price target raised to $36 from $26 at Mizuho
03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

05/25/21 B. Riley
NGM 'disappointing failure' in NASH a 'clearing event,' says B. Riley
05/25/21 BMO Capital
NGM Biopharmaceuticals price target lowered to $20 from $38 at BMO Capital
05/25/21 Raymond James
Raymond James downgrades two NASH players following NGM data
05/24/21 Piper Sandler
Piper says Madrigal's MAESTRO-NASH outcome not impacted by NGM ALPINE data
MEDXF Medexus Pharmaceuticals
$5.69 /

-0.06 (-1.04%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
FLXN Flexion
$8.86 /

-0.28 (-3.06%)

04/26/21 Credit Suisse
Flexion assumed with an Outperform at Credit Suisse
04/14/21 Raymond James
Flexion price target lowered to $16 from $18 at Raymond James
04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
HRMY Harmony Biosciences
$31.17 /

-0.83 (-2.59%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
TFX Teleflex
$404.93 /

+5.265 (+1.32%)

QDEL Quidel
$111.29 /

-0.5 (-0.45%)

PYPD PolyPid
$8.91 /

-0.11 (-1.22%)

NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

HRMY Harmony Biosciences
$31.17 /

-0.83 (-2.59%)

FLXN Flexion
$8.86 /

-0.28 (-3.06%)

ENTA Enanta
$46.35 /

+0.18 (+0.39%)

CYTK Cytokinetics
$22.15 /

+0.38 (+1.75%)

CBAY CymaBay
$4.48 /

-0.26 (-5.49%)

BWAY Brainsway
$10.30 /

-0.1 (-0.96%)

AYLA Ayala Pharmaceuticals
$11.00 /

+0.3 (+2.80%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

  • 23
    Feb
  • 21
    Jan
  • 21
    Jan
  • 06
    Jan
  • 18
    Sep
  • 19
    Aug
  • 17
    Jul
  • 26
    Jun
QDEL Quidel
$111.29 /

-0.5 (-0.45%)

QDEL Quidel
$111.29 /

-0.5 (-0.45%)

ONCS OncoSec
$3.40 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.37 /

+0.28 (+1.39%)

KDMN Kadmon
$3.83 /

-0.16 (-4.01%)

FLXN Flexion
$8.86 /

-0.28 (-3.06%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

ONCS OncoSec
$3.40 /

+ (+0.00%)

ATHA Athira Pharma
$10.33 /

-0.42 (-3.91%)

Conference/Events
Raymond James to hold a virtual conference » 04:55
06/22/21
06/22
04:55
06/22/21
04:55
TFX

Teleflex

$399.98 /

+3.115 (+0.78%)

, CBAY

CymaBay

$4.74 /

+0.09 (+1.94%)

, PYPD

PolyPid

$9.02 /

-0.19 (-2.06%)

, AYLA

Ayala Pharmaceuticals

$10.70 /

-0.13 (-1.20%)

, BWAY

Brainsway

$10.40 /

-0.1 (-0.95%)

, ENTA

Enanta

$46.24 /

+0.49 (+1.07%)

, KDMN

Kadmon

$3.99 /

+0.01 (+0.25%)

, ONCS

OncoSec

$3.40 /

-0.025 (-0.73%)

, ATHA

Athira Pharma

$10.75 /

-0.31 (-2.80%)

, QDEL

Quidel

$111.86 /

-1.855 (-1.63%)

, CYTK

Cytokinetics

$21.77 /

+0.46 (+2.16%)

, NGM

NGM Biopharmaceuticals

$20.08 /

-0.26 (-1.28%)

, MEDXF

Medexus Pharmaceuticals

$5.75 /

-0.2922 (-4.84%)

, FLXN

Flexion

$9.14 /

+ (+0.00%)

, HRMY

Harmony Biosciences

$32.00 /

+0.68 (+2.17%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 21-23.

ShowHide Related Items >><<
TFX Teleflex
$399.98 /

+3.115 (+0.78%)

QDEL Quidel
$111.86 /

-1.855 (-1.63%)

PYPD PolyPid
$9.02 /

-0.19 (-2.06%)

ONCS OncoSec
$3.40 /

-0.025 (-0.73%)

NGM NGM Biopharmaceuticals
$20.08 /

-0.26 (-1.28%)

MEDXF Medexus Pharmaceuticals
$5.75 /

-0.2922 (-4.84%)

KDMN Kadmon
$3.99 /

+0.01 (+0.25%)

HRMY Harmony Biosciences
$32.00 /

+0.68 (+2.17%)

FLXN Flexion
$9.14 /

+ (+0.00%)

ENTA Enanta
$46.24 /

+0.49 (+1.07%)

CYTK Cytokinetics
$21.77 /

+0.46 (+2.16%)

CBAY CymaBay
$4.74 /

+0.09 (+1.94%)

BWAY Brainsway
$10.40 /

-0.1 (-0.95%)

AYLA Ayala Pharmaceuticals
$10.70 /

-0.13 (-1.20%)

ATHA Athira Pharma
$10.75 /

-0.31 (-2.80%)

TFX Teleflex
$399.98 /

+3.115 (+0.78%)

05/18/21 Piper Sandler
Teleflex divestiture should accelerate sales growth, says Piper Sandler
05/10/21 Piper Sandler
Teleflex management surprised by post-earnings selloff, says Piper Sandler
04/30/21 SVB Leerink
Teleflex price target raised to $485 from $475 at SVB Leerink
02/25/21 Piper Sandler
Teleflex price target raised to $465 from $405 at Piper Sandler
CBAY CymaBay
$4.74 /

+0.09 (+1.94%)

06/21/21 Piper Sandler
Piper radar 'locked' on CymaBay EASL poster presentations on June 23
06/14/21 JonesTrading
JonesTrading starts CymaBay with Buy, $8 target on seladelpar potential
06/14/21 JonesTrading
CymaBay initiated with a Buy at JonesTrading
06/09/21 Piper Sandler
CymaBay to have 'impressive' lineup at EASL meeting, says Piper Sandler
PYPD PolyPid
$9.02 /

-0.19 (-2.06%)

11/24/20 Raymond James
Raymond James upgrades PolyPid to Strong Buy after BTD for D-PLEX
11/24/20 Raymond James
PolyPid upgraded to Strong Buy from Outperform at Raymond James
08/10/20 Alliance Global Partners
PolyPid initiated with a Buy at Alliance Global Partners
07/21/20 Raymond James
PolyPid initiated with an Outperform at Raymond James
AYLA Ayala Pharmaceuticals
$10.70 /

-0.13 (-1.20%)

12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
12/02/20
Fly Intel: Top five analyst initiations
12/02/20 Noble Capital
Ayala Pharmaceuticals initiated with an Outperform at Noble Capital
BWAY Brainsway
$10.40 /

-0.1 (-0.95%)

04/20/21 Northland
Brainsway initiated with an Outperform at Northland
02/17/21 Raymond James
Brainsway price target raised to $12 from $9 at Raymond James
ENTA Enanta
$46.24 /

+0.49 (+1.07%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
KDMN Kadmon
$3.99 /

+0.01 (+0.25%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
ONCS OncoSec
$3.40 /

-0.025 (-0.73%)

04/15/21 Alliance Global Partners
OncoSec price target raised to $11 from $6.50 at Alliance Global Partners
03/25/21 Maxim
OncoSec price target raised to $12 from $8 at Maxim
03/08/21
Fly Intel: Top five analyst initiations
03/08/21 BTIG
OncoSec initiated with a Buy at BTIG
ATHA Athira Pharma
$10.75 /

-0.31 (-2.80%)

06/18/21 Jefferies
Athira Pharma's 'unusual situation' to cause some volatility, says Jefferies
06/18/21 Stifel
Athira Pharma CEO leave situation 'impossible to really vet,' says Stifel
06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
QDEL Quidel
$111.86 /

-1.855 (-1.63%)

06/17/21 Craig-Hallum
Quidel price target lowered to $219 from $296 at Craig-Hallum
06/04/21 JPMorgan
Quidel price target lowered to $80 from $90 at JPMorgan
05/07/21 JPMorgan
Quidel price target lowered to $90 from $95 at JPMorgan
04/23/21 JPMorgan
Quidel price target lowered to $95 from $120 at JPMorgan
CYTK Cytokinetics
$21.77 /

+0.46 (+2.16%)

05/11/21 Mizuho
Cytokinetics price target raised to $36 from $26 at Mizuho
03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
NGM NGM Biopharmaceuticals
$20.08 /

-0.26 (-1.28%)

05/25/21 B. Riley
NGM 'disappointing failure' in NASH a 'clearing event,' says B. Riley
05/25/21 BMO Capital
NGM Biopharmaceuticals price target lowered to $20 from $38 at BMO Capital
05/25/21 Raymond James
Raymond James downgrades two NASH players following NGM data
05/24/21 Piper Sandler
Piper says Madrigal's MAESTRO-NASH outcome not impacted by NGM ALPINE data
MEDXF Medexus Pharmaceuticals
$5.75 /

-0.2922 (-4.84%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
FLXN Flexion
$9.14 /

+ (+0.00%)

04/26/21 Credit Suisse
Flexion assumed with an Outperform at Credit Suisse
04/14/21 Raymond James
Flexion price target lowered to $16 from $18 at Raymond James
04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
HRMY Harmony Biosciences
$32.00 /

+0.68 (+2.17%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
TFX Teleflex
$399.98 /

+3.115 (+0.78%)

QDEL Quidel
$111.86 /

-1.855 (-1.63%)

PYPD PolyPid
$9.02 /

-0.19 (-2.06%)

NGM NGM Biopharmaceuticals
$20.08 /

-0.26 (-1.28%)

HRMY Harmony Biosciences
$32.00 /

+0.68 (+2.17%)

FLXN Flexion
$9.14 /

+ (+0.00%)

ENTA Enanta
$46.24 /

+0.49 (+1.07%)

CYTK Cytokinetics
$21.77 /

+0.46 (+2.16%)

CBAY CymaBay
$4.74 /

+0.09 (+1.94%)

BWAY Brainsway
$10.40 /

-0.1 (-0.95%)

AYLA Ayala Pharmaceuticals
$10.70 /

-0.13 (-1.20%)

ATHA Athira Pharma
$10.75 /

-0.31 (-2.80%)

  • 23
    Feb
  • 21
    Jan
  • 21
    Jan
  • 06
    Jan
  • 18
    Sep
  • 19
    Aug
  • 17
    Jul
  • 26
    Jun
QDEL Quidel
$111.86 /

-1.855 (-1.63%)

QDEL Quidel
$111.86 /

-1.855 (-1.63%)

ONCS OncoSec
$3.40 /

-0.025 (-0.73%)

NGM NGM Biopharmaceuticals
$20.08 /

-0.26 (-1.28%)

KDMN Kadmon
$3.99 /

+0.01 (+0.25%)

FLXN Flexion
$9.14 /

+ (+0.00%)

ATHA Athira Pharma
$10.75 /

-0.31 (-2.80%)

ONCS OncoSec
$3.40 /

-0.025 (-0.73%)

ATHA Athira Pharma
$10.75 /

-0.31 (-2.80%)

Conference/Events
Raymond James to hold a virtual conference » 10:02
06/21/21
06/21
10:02
06/21/21
10:02
TFX

Teleflex

$394.92 /

-1.94 (-0.49%)

, CBAY

CymaBay

$4.71 /

+0.06 (+1.29%)

, PYPD

PolyPid

$9.20 /

-0.01 (-0.11%)

, AYLA

Ayala Pharmaceuticals

$10.83 /

+ (+0.00%)

, BWAY

Brainsway

$10.46 /

-0.04 (-0.38%)

, ENTA

Enanta

$45.88 /

+0.13 (+0.28%)

, KDMN

Kadmon

$4.00 /

+0.02 (+0.50%)

, ONCS

OncoSec

$3.39 /

-0.035 (-1.02%)

, ATHA

Athira Pharma

$11.35 /

+0.29 (+2.62%)

, QDEL

Quidel

$111.00 /

-2.715 (-2.39%)

, CYTK

Cytokinetics

$21.29 /

-0.02 (-0.09%)

, NGM

NGM Biopharmaceuticals

$20.00 /

-0.34 (-1.67%)

, MEDXF

Medexus Pharmaceuticals

$6.04 /

-0.1878 (-3.01%)

, FLXN

Flexion

$9.23 /

+0.09 (+0.98%)

, HRMY

Harmony Biosciences

$31.30 /

-0.02 (-0.06%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 21-23.

ShowHide Related Items >><<
TFX Teleflex
$394.92 /

-1.94 (-0.49%)

QDEL Quidel
$111.00 /

-2.715 (-2.39%)

PYPD PolyPid
$9.20 /

-0.01 (-0.11%)

ONCS OncoSec
$3.39 /

-0.035 (-1.02%)

NGM NGM Biopharmaceuticals
$20.00 /

-0.34 (-1.67%)

MEDXF Medexus Pharmaceuticals
$6.04 /

-0.1878 (-3.01%)

KDMN Kadmon
$4.00 /

+0.02 (+0.50%)

HRMY Harmony Biosciences
$31.30 /

-0.02 (-0.06%)

FLXN Flexion
$9.23 /

+0.09 (+0.98%)

ENTA Enanta
$45.88 /

+0.13 (+0.28%)

CYTK Cytokinetics
$21.29 /

-0.02 (-0.09%)

CBAY CymaBay
$4.71 /

+0.06 (+1.29%)

BWAY Brainsway
$10.46 /

-0.04 (-0.38%)

AYLA Ayala Pharmaceuticals
$10.83 /

+ (+0.00%)

ATHA Athira Pharma
$11.35 /

+0.29 (+2.62%)

TFX Teleflex
$394.92 /

-1.94 (-0.49%)

05/18/21 Piper Sandler
Teleflex divestiture should accelerate sales growth, says Piper Sandler
05/10/21 Piper Sandler
Teleflex management surprised by post-earnings selloff, says Piper Sandler
04/30/21 SVB Leerink
Teleflex price target raised to $485 from $475 at SVB Leerink
02/25/21 Piper Sandler
Teleflex price target raised to $465 from $405 at Piper Sandler
CBAY CymaBay
$4.71 /

+0.06 (+1.29%)

06/14/21 JonesTrading
JonesTrading starts CymaBay with Buy, $8 target on seladelpar potential
06/14/21 JonesTrading
CymaBay initiated with a Buy at JonesTrading
06/09/21 Piper Sandler
CymaBay to have 'impressive' lineup at EASL meeting, says Piper Sandler
03/31/21 Cantor Fitzgerald
CymaBay price target lowered to $7 from $20 at Cantor Fitzgerald
PYPD PolyPid
$9.20 /

-0.01 (-0.11%)

11/24/20 Raymond James
Raymond James upgrades PolyPid to Strong Buy after BTD for D-PLEX
11/24/20 Raymond James
PolyPid upgraded to Strong Buy from Outperform at Raymond James
08/10/20 Alliance Global Partners
PolyPid initiated with a Buy at Alliance Global Partners
07/21/20 Raymond James
PolyPid initiated with an Outperform at Raymond James
AYLA Ayala Pharmaceuticals
$10.83 /

+ (+0.00%)

12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
12/02/20
Fly Intel: Top five analyst initiations
12/02/20 Noble Capital
Ayala Pharmaceuticals initiated with an Outperform at Noble Capital
BWAY Brainsway
$10.46 /

-0.04 (-0.38%)

04/20/21 Northland
Brainsway initiated with an Outperform at Northland
02/17/21 Raymond James
Brainsway price target raised to $12 from $9 at Raymond James
ENTA Enanta
$45.88 /

+0.13 (+0.28%)

02/09/21 RBC Capital
Enanta price target raised to $53 from $47 at RBC Capital
01/29/21 JPMorgan
Enanta upgraded to Neutral with $55 target at JPMorgan
01/29/21 JPMorgan
Enanta upgraded to Neutral from Underweight at JPMorgan
01/08/21 Piper Sandler
Enanta remains 'significantly undervalued,' says Piper Sandler
KDMN Kadmon
$4.00 /

+0.02 (+0.50%)

06/04/21 Mizuho
Kadmon's KD022 results a positive start for immuno-oncology program, says Mizuho
05/20/21 UBS
Kadmon initiated with a Buy at UBS
03/11/21 Oppenheimer
Kadmon should be bought on weakness from FDA extension, says Oppenheimer
02/10/21 Jefferies
Survey points to 'encouraging' signs for Kadmon's belumosudil, says Jefferies
ONCS OncoSec
$3.39 /

-0.035 (-1.02%)

04/15/21 Alliance Global Partners
OncoSec price target raised to $11 from $6.50 at Alliance Global Partners
03/25/21 Maxim
OncoSec price target raised to $12 from $8 at Maxim
03/08/21
Fly Intel: Top five analyst initiations
03/08/21 BTIG
OncoSec initiated with a Buy at BTIG
ATHA Athira Pharma
$11.35 /

+0.29 (+2.62%)

06/18/21 Jefferies
Athira Pharma's 'unusual situation' to cause some volatility, says Jefferies
06/18/21 Stifel
Athira Pharma CEO leave situation 'impossible to really vet,' says Stifel
06/07/21 JMP Securities
Aducanumab accelerated approval positive for Athira, others, says JMP Securities
06/07/21 Goldman Sachs
Goldman says Biogen approval has positive read to Alector, Athira
QDEL Quidel
$111.00 /

-2.715 (-2.39%)

06/17/21 Craig-Hallum
Quidel price target lowered to $219 from $296 at Craig-Hallum
06/04/21 JPMorgan
Quidel price target lowered to $80 from $90 at JPMorgan
05/07/21 JPMorgan
Quidel price target lowered to $90 from $95 at JPMorgan
04/23/21 JPMorgan
Quidel price target lowered to $95 from $120 at JPMorgan
CYTK Cytokinetics
$21.29 /

-0.02 (-0.09%)

05/11/21 Mizuho
Cytokinetics price target raised to $36 from $26 at Mizuho
03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
NGM NGM Biopharmaceuticals
$20.00 /

-0.34 (-1.67%)

05/25/21 B. Riley
NGM 'disappointing failure' in NASH a 'clearing event,' says B. Riley
05/25/21 BMO Capital
NGM Biopharmaceuticals price target lowered to $20 from $38 at BMO Capital
05/25/21 Raymond James
Raymond James downgrades two NASH players following NGM data
05/24/21 Piper Sandler
Piper says Madrigal's MAESTRO-NASH outcome not impacted by NGM ALPINE data
MEDXF Medexus Pharmaceuticals
$6.04 /

-0.1878 (-3.01%)

06/18/21 Canaccord
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord
03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
FLXN Flexion
$9.23 /

+0.09 (+0.98%)

04/26/21 Credit Suisse
Flexion assumed with an Outperform at Credit Suisse
04/14/21 Raymond James
Flexion price target lowered to $16 from $18 at Raymond James
04/06/21 RBC Capital
Flexion transferred with an Outperform at RBC Capital
08/20/20 Goldman Sachs
Flexion initiated with a Neutral at Goldman Sachs
HRMY Harmony Biosciences
$31.30 /

-0.02 (-0.06%)

03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
09/14/20 Jefferies
Harmony Biosciences initiated with a Buy at Jefferies
09/14/20 Piper Sandler
Harmony Biosciences initiated with an Overweight at Piper Sandler
09/13/20 Goldman Sachs
Harmony Biosciences initiated with a Neutral at Goldman Sachs
TFX Teleflex
$394.92 /

-1.94 (-0.49%)

QDEL Quidel
$111.00 /

-2.715 (-2.39%)

PYPD PolyPid
$9.20 /

-0.01 (-0.11%)

NGM NGM Biopharmaceuticals
$20.00 /

-0.34 (-1.67%)

HRMY Harmony Biosciences
$31.30 /

-0.02 (-0.06%)

FLXN Flexion
$9.23 /

+0.09 (+0.98%)

ENTA Enanta
$45.88 /

+0.13 (+0.28%)

CYTK Cytokinetics
$21.29 /

-0.02 (-0.09%)

CBAY CymaBay
$4.71 /

+0.06 (+1.29%)

BWAY Brainsway
$10.46 /

-0.04 (-0.38%)

AYLA Ayala Pharmaceuticals
$10.83 /

+ (+0.00%)

ATHA Athira Pharma
$11.35 /

+0.29 (+2.62%)

  • 23
    Feb
  • 21
    Jan
  • 21
    Jan
  • 06
    Jan
  • 18
    Sep
  • 19
    Aug
  • 17
    Jul
  • 26
    Jun
QDEL Quidel
$111.00 /

-2.715 (-2.39%)

QDEL Quidel
$111.00 /

-2.715 (-2.39%)

ONCS OncoSec
$3.39 /

-0.035 (-1.02%)

NGM NGM Biopharmaceuticals
$20.00 /

-0.34 (-1.67%)

KDMN Kadmon
$4.00 /

+0.02 (+0.50%)

FLXN Flexion
$9.23 /

+0.09 (+0.98%)

ATHA Athira Pharma
$11.35 /

+0.29 (+2.62%)

ONCS OncoSec
$3.39 /

-0.035 (-1.02%)

ATHA Athira Pharma
$11.35 /

+0.29 (+2.62%)

Recommendations
Medexus Pharmaceuticals price target lowered to C$9 from C$9.50 at Canaccord » 11:25
06/18/21
06/18
11:25
06/18/21
11:25
MEDXF

Medexus Pharmaceuticals

$6.23 /

-0.17 (-2.66%)

Canaccord analyst Tania…

Canaccord analyst Tania Gonsalves lowered the firm's price target on Medexus Pharmaceuticals to C$9 from C$9.50 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
MEDXF Medexus Pharmaceuticals
$6.23 /

-0.17 (-2.66%)

MEDXF Medexus Pharmaceuticals
$6.23 /

-0.17 (-2.66%)

03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
Hot Stocks
Medexus bolsters medical affairs team in preparation for treosulfan launch » 08:42
06/10/21
06/10
08:42
06/10/21
08:42
MEDXF

Medexus Pharmaceuticals

$6.27 /

-0.0132 (-0.21%)

Medexus Pharmaceuticals…

Medexus Pharmaceuticals announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating agent, in the United States. reosulfan is an agent developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. With more than 100 publications supporting its safety and efficacy, management believes treosulfan is ideally positioned to become the new standard of care in the U.S. As such, pro-actively putting in place the right people and resources ahead of the scheduled Prescription Drug User Fee Act date, which is set for August 2021, is critical to both the successful and timely launch of this innovative product for the benefit of patients and maximizing the value of the seven and a half years of exclusivity the Company expects to receive upon FDA approval. The hires of Keith Steward, MD, MBA, Senior Vice President of Medical Affairs, J. Lynn Bass, B.S, PharmD, Senior Director of Medical Sciences and Mark Fosdal, DHSc, PA-C, Director, Scientific Communications are all part of that pro-active plan. Steward served as Global Head of Medical Affairs at QED Therapeutics. Bass served as Senior Director and Head of Medical Science Liaisons at Mesoblast. Fosdal, DHSc, PA-C, served as Executive Medical Science Liaison at Atara Biotherapeutics.

ShowHide Related Items >><<
MEDXF Medexus Pharmaceuticals
$6.27 /

-0.0132 (-0.21%)

03/03/21 Canaccord
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord
02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
Over a quarter ago
Upgrade
Medexus Pharmaceuticals upgraded to Buy from Hold at Canaccord » 07:05
03/03/21
03/03
07:05
03/03/21
07:05
MEDXF

Medexus Pharmaceuticals

$0.00 /

+ (+0.00%)

Canaccord analyst Tania…

Canaccord analyst Tania Gonsalves upgraded Medexus Pharmaceuticals to Buy from Hold with an unchanged price target of C$9.50. The recent selloff in the shares presents a buying opportunity, Gonsalves tells investors in a research note.

ShowHide Related Items >><<
MEDXF Medexus Pharmaceuticals
$0.00 /

+ (+0.00%)

02/24/21 Stifel
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel
Recommendations
Medexus Pharmaceuticals price target raised to C$17.50 from C$7.25 at Stifel » 11:05
02/24/21
02/24
11:05
02/24/21
11:05
MEDXF

Medexus Pharmaceuticals

$0.00 /

+ (+0.00%)

Stifel analyst Justin…

Stifel analyst Justin Keywood raised the firm's price target on Medexus Pharmaceuticals to C$17.50 from C$7.25 and keeps a Buy rating on the shares. The analyst estimates the company's exclusive licensing deal for Treosulfan "essentially doubles the value" of the stock, leading to the significant target price increase.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.